STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 97 filers reported holding STOKE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,017,718 | -71.9% | 258,422 | -24.0% | 0.00% | -100.0% |
| Q2 2023 | $3,615,364 | +47.8% | 340,145 | +15.8% | 0.00% | 0.0% |
| Q1 2023 | $2,445,748 | +90651.3% | 293,632 | +0.6% | 0.00% | 0.0% |
| Q4 2022 | $2,695 | -99.9% | 292,007 | -13.9% | 0.00% | -50.0% |
| Q3 2022 | $4,353,000 | +24.3% | 338,996 | +27.9% | 0.00% | +100.0% |
| Q2 2022 | $3,501,000 | +9.6% | 265,021 | +74.7% | 0.00% | 0.0% |
| Q1 2022 | $3,194,000 | +84.5% | 151,660 | +110.2% | 0.00% | 0.0% |
| Q4 2021 | $1,731,000 | +52.1% | 72,142 | +61.3% | 0.00% | – |
| Q3 2021 | $1,138,000 | -67.9% | 44,719 | -57.6% | 0.00% | -100.0% |
| Q2 2021 | $3,547,000 | -15.9% | 105,383 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $4,218,000 | +71.1% | 108,823 | +173.3% | 0.00% | 0.0% |
| Q4 2020 | $2,465,000 | +898.0% | 39,813 | +439.4% | 0.00% | – |
| Q3 2020 | $247,000 | – | 7,381 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |